Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.74 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.74 |
| ▸ | PRNP | P04156 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.74 |
| ▸ | PPARG | P37231 | 1/20 | 0.74 |
| ▸ | HTT | P42858 | 1/20 | 0.74 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.74 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.74 |
| ▸ | MAPT | P10636 | 7/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.72 |
| ▸ | GAA | P10253 | 2/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6656891 | 0.89 | MAPK1 (0.58) | NPSR1MAPK1RXFP1PRNPTSHR | |
| SCHEMBL3102501 | 0.86 | RXFP1 (0.76) | NPSR1MAPK1RXFP1PRNPTSHR | |
| SCHEMBL5453267 | 0.86 | RXFP1 (0.76) | NPSR1MAPK1RXFP1PRNPTSHR | |
| SCHEMBL18960346 | 0.86 | RXFP1 (0.76) | NPSR1MAPK1RXFP1PRNPTSHR | |
| SCHEMBL18970426 | 0.85 | MAPT (0.78) | NPSR1MAPK1RXFP1PRNPTSHR | |
| SCHEMBL5023563 | 0.85 | MCL1 (0.70) | NPSR1MAPK1RXFP1PRNPTSHR | |
| Ammonia Solution, Strong SCHEMBL28931345 | 0.85 | RXFP1 (0.74) | NPSR1MAPK1RXFP1PRNPTSHR | |
| SCHEMBL8414188 | 0.84 | MAPT (1.00) | NPSR1MAPK1RXFP1PRNPTSHR | |
| SCHEMBL12501358 | 0.84 | MAPK1 (0.56) | NPSR1MAPK1RXFP1PRNPTSHR | |
| SCHEMBL693146 | 0.84 | BCKDK (0.68) | NPSR1MAPK1RXFP1PRNPTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210171554-A1 | BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS TO TREAT MEDICAL DISORDERS | G1 THERAPEUTICS, INC. (US) | 2021-06-10 | — | — | US | disclosed |
| CN-112839646-A | Benzothiophene estrogen receptor modulators for the treatment of medical disorders | G1治疗公司 | 2021-05-25 | — | — | CN | disclosed |
| US-10981887-B2 | Benzothiophene estrogen receptor modulators | G1 THERAPEUTICS, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20200216406-A1 | BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS | G1 THERAPEUTICS, INC. (US) | 2020-07-09 | — | — | US | disclosed |
| US-10208011-B2 | Benzothiophene estrogen receptor modulators | G1 THERAPEUTICS, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-5863936-A | HETEROCYCLIC ENZYME INHIBITORS AS ANTICANCER AGENTS | GERON CORPORATION (US) | 1999-01-26 | — | — | US | disclosed |
| US-5760062-A | ANTICANCER AGENTS | GERON CORPORATION (US) | 1998-06-02 | — | — | US | disclosed |
| US-5703116-A | TREATING CANCER | GERON CORPORATION (US) | 1997-12-30 | — | — | US | disclosed |
| US-4396621-A | ANALGESICS, ANTIIMFLAMMATORY AGENTS | CIBA-GEIGY CORPORATION (US) | 1983-08-02 | — | — | US | disclosed |
| US-4320138-A | ANTIINFLAMMATORY AGENTS FOR ARTHRITIS, GOUT | CIBA-GEIGY CORPORATION (US) | 1982-03-16 | — | — | US | disclosed |
| US-4260779-A | ANALGESICS, ANTIINFLAMMATORY, DIURETICS | CIBA-GEIGY CORPORATION (US) | 1981-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10981887-B2 | Benzothiophene estrogen receptor modulators | ESR1, GPER1, ESR2 | NPSR1 268/4885MAPK1 2583/4885RXFP1 730/4885 |
| US-10208011-B2 | Benzothiophene estrogen receptor modulators | ESR1, GPER1, ESR2 | NPSR1 268/4885MAPK1 2583/4885RXFP1 730/4885 |
| US-20200216406-A1 | BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS | ESR1, GPER1, ESR2 | NPSR1 268/4885MAPK1 2583/4885RXFP1 730/4885 |
| US-20210171554-A1 | BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS TO TREAT MEDICAL DISORDERS | CDK6, ESR1, CDK4 | NPSR1 1563/4885MAPK1 449/4885RXFP1 3184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.